Last reviewed · How we verify
GC3111 vaccine
GC3111 vaccine is a Biologic drug developed by Green Cross Corporation. It is currently in Phase 2 development. Also known as: GC3111.
At a glance
| Generic name | GC3111 vaccine |
|---|---|
| Also known as | GC3111 |
| Sponsor | Green Cross Corporation |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3111 in Healthy Adults (PHASE2)
- Safety and Immunogenicity Study of Tetanus, Diphtheria and Acellular Pertussis (Tdap) Vaccine (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GC3111 vaccine CI brief — competitive landscape report
- GC3111 vaccine updates RSS · CI watch RSS
- Green Cross Corporation portfolio CI
Frequently asked questions about GC3111 vaccine
What is GC3111 vaccine?
GC3111 vaccine is a Biologic drug developed by Green Cross Corporation.
Who makes GC3111 vaccine?
GC3111 vaccine is developed by Green Cross Corporation (see full Green Cross Corporation pipeline at /company/green-cross-corporation).
Is GC3111 vaccine also known as anything else?
GC3111 vaccine is also known as GC3111.
What development phase is GC3111 vaccine in?
GC3111 vaccine is in Phase 2.
Related
- Manufacturer: Green Cross Corporation — full pipeline
- Also known as: GC3111
- Compare: GC3111 vaccine vs similar drugs
- Pricing: GC3111 vaccine cost, discount & access